drug
suscept
defin
minim
inhibitori
concentr
mic
often
predict
whether
fungal
infect
respond
therapi
clinic
toler
supram
antifung
drug
concentr
rare
quantifi
current
clinic
recommend
suggest
ignor
measur
character
drugrespons
variabl
could
influenc
outcom
fungal
infect
generaliz
across
major
clade
candida
albican
one
frequent
isol
human
fungal
pathogen
quantifi
antifung
toler
fraction
growth
fog
mic
found
clearli
distinct
susceptibilityresist
measur
mic
instead
toler
due
slow
growth
subpopul
cell
overcom
drug
stress
effici
rest
popul
correl
invers
accumul
intracellular
drug
importantli
mani
adjuv
drug
use
togeth
fluconazol
fungistat
drug
reduc
toler
without
affect
resist
includ
inhibitor
major
stress
respons
hub
calcineurin
tor
accordingli
invertebr
infect
model
adjuv
combin
therapi
significantli
effect
fluconazol
alon
treat
highli
toler
isol
improv
treatment
isol
low
toler
level
furthermor
isol
recov
immunocompet
patient
persist
candidemia
display
significantli
higher
toler
isol
readili
clear
fluconazol
thu
toler
correl
respons
fluconazol
therapi
patient
may
help
predict
whether
infect
respond
fluconazol
alon
similarli
measur
toler
may
provid
use
clinic
paramet
choos
appropri
therapeut
strategi
overcom
persist
clinic
candidemia
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
goal
antimicrobi
suscept
test
predict
clinic
success
failur
antibiot
therapi
infect
recalcitr
drug
treatment
due
resist
refer
microbi
growth
presenc
drug
concentr
inhibit
suscept
isol
suscept
commonli
measur
minim
inhibitori
concentr
mic
h
growth
presenc
drug
fungal
infect
gener
follow
rule
predict
therapeut
outcom
base
vitro
suscept
test
suscept
isol
resist
isol
respond
therapi
impli
infect
outcom
influenc
host
factor
well
featur
pathogen
reflect
mic
effect
organ
caus
persist
infect
defin
clear
cours
antifung
treatment
similar
suscept
organ
readili
clear
cours
antifung
treatment
accordingli
import
identifi
measur
paramet
contribut
diseas
sever
four
class
antifung
current
clinic
use
resist
azol
includ
fluconazol
flc
commonli
administ
antifung
candida
speci
increas
problem
alter
drug
uptakedrug
efflux
chang
ergosterol
biosynthesi
target
azol
drug
major
known
mechan
azol
resist
stress
respons
propos
third
mechan
antifung
resist
broad
rang
small
molecul
enhanc
antifung
activ
vitro
vivo
inhibitor
calcineurin
tor
promin
among
combin
therapi
use
antifung
togeth
inhibitor
propos
promis
strategi
extend
efficaci
current
drug
addit
sever
psychotherapeut
agent
fluoxetin
fluphenazin
sertralin
enhanc
flc
activ
fungal
speci
whether
adjuv
affect
therapeut
outcom
remain
address
persist
candidemia
defin
failur
clear
bloodstream
infect
caus
suscept
organ
associ
increas
mortal
one
studi
mortal
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
rate
among
infect
persist
candidemia
among
persist
candidemia
mechan
underli
persist
candidemia
may
includ
variabl
pharmacolog
drug
suboptim
dose
presenc
fungal
biofilm
indwel
cathet
reduc
immun
posit
respons
drug
captur
measur
mic
alon
addit
paramet
could
use
predict
likelihood
clinic
isol
might
respond
poorli
antifung
drug
furthermor
understand
mechan
underli
paramet
critic
develop
new
therapeut
approach
persist
candida
infect
mic
measur
optim
minim
ignor
residu
fungal
growth
term
toler
trail
growth
discuss
literatur
year
detect
clinic
isol
recommend
base
upon
studi
acut
infect
use
mous
model
bloodstream
candidiasi
observ
isol
high
trail
growth
mucos
infect
respond
posit
short
term
antifung
treatment
despit
later
recurr
infect
trail
growth
sensit
environment
condit
includ
ph
temperatur
nutrient
usual
detect
liquid
cultur
definit
toler
vari
gener
describ
surviv
growth
inhibitori
concentr
detect
slow
growth
within
zone
inhibit
use
estrip
disk
diffus
assay
broth
microdilut
assay
toler
affect
sever
adjuv
drug
iron
level
gene
involv
vacuolar
protein
sort
well
calcium
flux
howev
precis
relationship
outcom
fungal
infect
toler
trail
growth
determin
toler
cell
continu
divid
presenc
antifung
postul
contribut
persist
andor
recurr
fungal
infect
measur
suscept
toler
broad
rang
clinic
isol
span
major
c
albican
clade
ask
paramet
influenc
fungal
infect
outcom
analyz
disk
diffus
assay
use
diskimag
quantifi
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
radiu
rad
zone
inhibit
paramet
relat
mic
fraction
growth
fog
within
zone
inhibit
paramet
measur
toler
found
rang
adjuv
drug
use
combin
flc
increas
drug
cidal
reduc
fog
mic
effect
vitro
vivo
inhibit
strain
high
low
fog
level
final
highli
toler
isol
associ
persist
candidemia
suggest
know
toler
level
infect
isol
may
import
clinic
implic
may
inform
treatment
option
result
toler
measur
fog
distinct
drug
resist
quantifi
drug
respons
c
albican
isol
differ
genet
background
type
infect
use
diskimag
quantit
analysi
tool
measur
rad
radiu
zone
inhibit
indic
suscept
relat
mic
fog
fraction
growth
within
zone
inhibit
rel
maximum
possibl
growth
fig
screen
clinic
isol
supplementari
tabl
reveal
fog
level
rang
wide
correl
rad
level
fig
c
indic
fog
rad
measur
independ
drug
respons
fog
detect
respons
drug
includ
fungistat
antifung
azol
lesser
degre
fungicid
agent
supplementari
fig
seri
strain
deriv
passag
particularli
sensit
media
differ
lower
rad
higher
fog
level
rich
medium
ypd
casiton
medium
supplementari
fig
emphas
assay
must
perform
consist
condit
ensur
reproduc
result
importantli
fogsmg
independ
cell
densiti
importantli
result
establish
fog
level
repres
proport
popul
form
coloni
grow
mic
area
occupi
light
pixel
chang
area
time
proxi
coloni
size
growth
rate
respect
differ
c
albican
isol
exhibit
differ
initi
time
fig
f
notabl
toa
flc
toa
without
flc
high
fog
isol
shorter
low
fog
isol
fig
correl
overal
fog
level
fig
suggest
high
fog
strain
overcom
inhibitori
pressur
antifung
effici
low
fog
strain
consist
liquid
assay
drug
highli
toler
isol
also
display
shorter
lag
time
relat
isol
low
toler
level
supplementari
fig
number
c
albican
growth
paramet
correl
fog
level
includ
cell
viabil
presenc
drug
fig
consist
flc
fungistat
rather
fungicid
unlik
toler
bacteria
display
reduc
growth
rate
longer
coloni
appear
time
antifung
toler
correl
slower
growth
three
decreas
intracellular
drug
level
underli
increas
toler
recent
develop
fluoresc
azol
probe
provid
power
tool
monitor
intracellular
drug
level
uptak
rate
use
flow
cytometri
fig
initi
rate
uptak
per
cell
vari
strain
show
weak
invers
correl
fog
level
r
p
fig
contrast
steadi
state
level
h
correl
invers
fog
level
r
p
fig
cell
categor
low
mid
high
level
base
assumpt
steadi
state
drug
level
influenc
drug
efflux
uptak
measur
efflux
dye
remov
primarili
via
abc
class
transport
gener
rate
efflux
higher
presenc
absenc
flc
notabl
except
fig
supplementari
fig
yet
efflux
rate
correl
fog
condit
test
supplementari
fig
r
thu
determin
steadi
state
intracellular
flc
level
complex
includ
uptak
efflux
rate
well
factor
fig
fluoxetin
serotonin
inhibitor
fluphenazin
antipsychot
drug
stimul
abc
transport
express
indirectli
inhibit
calcineurin
via
calmodulin
flc
adjuv
clear
toler
clinic
isol
test
fig
b
well
longitudin
seri
singl
hiv
patient
acquir
resist
time
set
persist
nonpersist
clinic
isol
supplementari
fig
importantli
adjuv
littl
effect
radmic
level
fig
b
supplementari
fig
taken
togeth
experi
demonstr
toler
intrins
properti
distinct
drug
suscept
toler
level
correl
infect
resist
azol
treatment
clinic
current
decis
therapeut
strategi
treat
candida
infect
base
upon
patient
statu
infect
speci
antifung
suscept
clinic
mic
assay
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
discov
isol
higher
toler
level
cell
lower
intracellular
drug
level
toler
function
either
uptak
efflux
rate
despit
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
wellknown
role
efflux
drug
resist
factor
uptak
efflux
impact
intracellular
flc
level
remain
determin
via
effect
toler
resist
two
import
implic
first
subpopul
natur
toler
suggest
stress
pathway
must
exhibit
celltocel
distinct
resist
toler
consist
mechan
virul
assay
perform
strain
isol
passag
day
either
ypd
alon
low
fog
isol
ypd
plu
flc
high
fog
isol
isol
clinic
isol
set
see
supplementari
tabl
experi
perform
duplic
n
larva
statist
differ
larval
group
test
use
mantelcox
test
neg
control
includ
pb
flc
alon
flc
fnz
group
larva
signific
kill
larva
observ
either
condit
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
